Platinum-resistant Ovarian Carcinoma
📧 Sign up to get email alerts when something new happens for Platinum-resistant Ovarian Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer [Phase 1]
Phase 1 clinical trial assessing different dosing amounts of the drug combination M1774 and ZEN-3694 for recurrent ovarian and endometrial c…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]
Phase 2 clinical trial evaluating Bevacizumab in combination with Anetumab Ravtansine or Paclitaxel for refractory ovarian, fallopian tube, …
-
CLINICAL_TRIALS research · 2026-03-16Clinical Trial Update: Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer [Phase 2]
A Phase 2 clinical trial evaluating pembrolizumab in combination with bevacizumab, with or without the anti-CD40 agonist CDX-1140, for recur…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer [Phase 2]
A Phase 2 trial sponsored by Emory University is investigating repurposed atovaquone for platinum-resistant ovarian cancer, with recruitment…